- Home
- CNK vs RARE Comparison
CNK vs RARE Comparison
Compare CNK & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNK
- RARE
- Stock Information
- Founded
- CNK 1984
- RARE 2010
- Country
- CNK United States
- RARE United States
- Employees
- CNK N/A
- RARE N/A
- Industry
- CNK Movies/Entertainment
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CNK Consumer Discretionary
- RARE Health Care
- Exchange
- CNK Nasdaq
- RARE Nasdaq
- Market Cap
- CNK 3.4B
- RARE 3.2B
- IPO Year
- CNK 2007
- RARE 2014
- Fundamental
- Price
- CNK $30.14
- RARE $32.05
- Analyst Decision
- CNK Strong Buy
- RARE Strong Buy
- Analyst Count
- CNK 10
- RARE 14
- Target Price
- CNK $35.30
- RARE $87.71
- AVG Volume (30 Days)
- CNK 2.9M
- RARE 1.3M
- Earning Date
- CNK 11-05-2025
- RARE 11-04-2025
- Dividend Yield
- CNK 1.06%
- RARE N/A
- EPS Growth
- CNK N/A
- RARE N/A
- EPS
- CNK 1.11
- RARE N/A
- Revenue
- CNK $3,153,000,000.00
- RARE $630,598,000.00
- Revenue This Year
- CNK $7.03
- RARE $19.65
- Revenue Next Year
- CNK $7.63
- RARE $23.65
- P/E Ratio
- CNK $27.04
- RARE N/A
- Revenue Growth
- CNK 9.70
- RARE 20.63
- 52 Week Low
- CNK $23.12
- RARE $25.81
- 52 Week High
- CNK $36.28
- RARE $50.00
- Technical
- Relative Strength Index (RSI)
- CNK 63.52
- RARE 46.51
- Support Level
- CNK $28.95
- RARE $29.36
- Resistance Level
- CNK $30.77
- RARE $34.01
- Average True Range (ATR)
- CNK 1.07
- RARE 1.58
- MACD
- CNK 0.18
- RARE -0.17
- Stochastic Oscillator
- CNK 84.68
- RARE 49.93
About CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.